| scholarly article | Q13442814 |
| P50 | author | Ralph Steinman | Q105494 |
| Annette Oxenius | Q87490341 | ||
| Régis Josien | Q48295383 | ||
| P2093 | author name string | B R Wong | |
| Y Choi | |||
| M F Bachmann | |||
| P2860 | cites work | Disruption of CD40-CD40 ligand interactions results in an enhanced susceptibility to Leishmania amazonensis infection. | Q52519428 |
| Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways | Q56908985 | ||
| CD40 ligand-transduced co-stimulation of T cells in the development of helper function | Q58882277 | ||
| Protective role of CD40 in Leishmania major infection at two distinct phases of cell-mediated immunity | Q71066501 | ||
| CD40 ligand is required for protective cell-mediated immunity to Leishmania major | Q71066505 | ||
| Dendritic cells produce IL-12 and direct the development of Th1 cells from naive CD4+ T cells | Q72191659 | ||
| CD40 AND CD154 IN CELL-MEDIATED IMMUNITY | Q22255634 | ||
| TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells | Q24315251 | ||
| Reduction of atherosclerosis in mice by inhibition of CD40 signalling | Q24316540 | ||
| A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function | Q24336057 | ||
| Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation | Q24677534 | ||
| Dendritic cells and the control of immunity | Q27860918 | ||
| The immune responses in CD40-deficient mice: impaired immunoglobulin class switching and germinal center formation | Q28586300 | ||
| Impairment of antigen-specific T-cell priming in mice lacking CD40 ligand | Q34367466 | ||
| CD40 ligand-deficient mice generate a normal primary cytotoxic T-lymphocyte response but a defective humoral response to a viral infection | Q35873254 | ||
| Immunodeficiency with hyper-IgM (HIM) | Q35950781 | ||
| CD40-CD40 ligand interactions are critical in T-B cooperation but not for other anti-viral CD4+ T cell functions | Q36366592 | ||
| Induction of long-lived germinal centers associated with persisting antigen after viral infection | Q36366635 | ||
| High level IL-12 production by murine dendritic cells: upregulation via MHC class II and CD40 molecules and downregulation by IL-4 and IL-10. | Q36367196 | ||
| TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor | Q36380989 | ||
| Origin, maturation and antigen presenting function of dendritic cells. | Q40906220 | ||
| Immune regulation by CD40 and its ligand GP39. | Q41039754 | ||
| CD40-CD40 ligand: a multifunctional receptor-ligand pair. | Q41134276 | ||
| CD40L-deficient mice show deficits in antiviral immunity and have an impaired memory CD8+ CTL response. | Q41898717 | ||
| Interleukin-12 is required for interferon-gamma production and lethality in lipopolysaccharide-induced shock in mice. | Q44100288 | ||
| T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions | Q47982736 | ||
| Help for cytotoxic-T-cell responses is mediated by CD40 signalling | Q47982749 | ||
| A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell | Q47982760 | ||
| Requirement for CD40 ligand in costimulation induction, T cell activation, and experimental allergic encephalomyelitis. | Q48913563 | ||
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 1025-1031 | |
| P577 | publication date | 1999-04-01 | |
| P1433 | published in | Journal of Experimental Medicine | Q3186912 |
| P1476 | title | TRANCE, a tumor necrosis factor family member critical for CD40 ligand-independent T helper cell activation | |
| P478 | volume | 189 |
| Q24291798 | A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells |
| Q34087699 | A novel helper role for CD4 T cells |
| Q24675157 | A novel member of the leukocyte receptor complex regulates osteoclast differentiation |
| Q27005894 | A review of denosumab for the treatment of osteoporosis |
| Q39514622 | Activated T cells induce macrophages to produce NO and control Leishmania major in the absence of tumor necrosis factor receptor p55. |
| Q28235728 | An essential function for the nuclear receptor RORgamma(t) in the generation of fetal lymphoid tissue inducer cells |
| Q35750515 | Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis |
| Q73420690 | Bacterial CpG-DNA activates dendritic cells in vivo: T helper cell-independent cytotoxic T cell responses to soluble proteins |
| Q34712635 | Balancing protective immunity and immunopathology |
| Q28265584 | Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab |
| Q35145622 | Biology of the TRANCE axis |
| Q57202273 | Blocking T-cell costimulation in transplantation: opportunities and challenges |
| Q24805600 | Bone loss. Therapeutic approaches for preventing bone loss in inflammatory arthritis |
| Q38288576 | CD154-dependent priming of diabetogenic CD4(+) T cells dissociated from activation of antigen-presenting cells |
| Q24299911 | CD40 Ligand Blocks Apoptosis Induced by Tumor Necrosis Factor α, Glucocorticoids, and Etoposide in Osteoblasts and the Osteocyte-Like Cell Line Murine Long Bone Osteocyte-Y4 |
| Q36375919 | CD40-independent pathways of T cell help for priming of CD8(+) cytotoxic T lymphocytes |
| Q30433070 | CD70 expression by dendritic cells plays a critical role in the immunogenicity of CD40-independent, CD4+ T cell-dependent, licensed CD8+ T cell responses |
| Q24806926 | Cell fate decision: T-helper 1 and 2 subsets in immune responses |
| Q44415928 | Chemokines and TRANCE as genetic adjuvants for a DNA vaccine to rabies virus |
| Q35901092 | Clinical development of anti-RANKL therapy |
| Q40124936 | Co-immunisation with DNA encoding RANK/RANKL or 4-1BBL costimulatory molecules does not enhance effector or memory CTL responses afforded by immunisation with a tumour antigen-encoding DNA vaccine |
| Q34201118 | Constitutive expression of TNF-related activation-induced cytokine (TRANCE)/receptor activating NF-κB ligand (RANK)-L by rat plasmacytoid dendritic cells |
| Q41160055 | Cutaneous RANK-RANKL Signaling Upregulates CD8-Mediated Antiviral Immunity during Herpes simplex Virus Infection by Preventing Virus-Induced Langerhans Cell Apoptosis |
| Q33970977 | Cytokines and T cells in host defense |
| Q46091534 | DAP12-deficient mice fail to develop autoimmunity due to impaired antigen priming |
| Q33850712 | Dendritic cells in experimental allergic encephalomyelitis and multiple sclerosis |
| Q37986124 | Denosumab for treatment of breast cancer bone metastases and beyond |
| Q34545263 | Denosumab: targeting the RANKL pathway to treat rheumatoid arthritis. |
| Q73566974 | Development of improved soluble inhibitors of FasL and CD40L based on oligomerized receptors |
| Q47891265 | Direct activation of dendritic cells by the malaria parasite, Plasmodium chabaudi chabaudi |
| Q28295303 | Disorders of bone remodeling |
| Q37767159 | Do RANKL inhibitors (denosumab) affect inflammation and immunity? |
| Q37441693 | Effects of RANKL-Targeted Therapy in Immunity and Cancer |
| Q34162783 | Effects of antiresorptive agents on osteomyelitis: novel insights into the pathogenesis of osteonecrosis of the jaw. |
| Q85892534 | Efficacy of phytol-derived diterpenoid immunoadjuvants over alum in shaping the murine host's immune response to Staphylococcus aureus |
| Q21131222 | Emerging Functions of RANKL in Lymphoid Tissues |
| Q28210874 | Enhanced CD4+ T cell proliferation and Th2 cytokine production in DR6-deficient mice |
| Q40628569 | Enhanced Effector and Memory CTL Responses Generated by Incorporation of Receptor Activator of NF-κB (RANK)/RANK Ligand Costimulatory Molecules into Dendritic Cell Immunogens Expressing a Human Tumor-Specific Antigen |
| Q35039002 | Gene-modified dendritic cells for immunotherapy against cancer |
| Q33232238 | High expression of antioxidant proteins in dendritic cells: possible implications in atherosclerosis. |
| Q41137165 | IL-10 critically modulates B cell responsiveness in Rankl-/- mice. |
| Q53584487 | Identification of novel RANK polymorphisms and their putative association with low BMD among postmenopausal women. |
| Q34111806 | Immune responses against a single CD8+-T-cell epitope induced by virus vector vaccination can successfully control Trypanosoma cruzi infection |
| Q28141017 | Immunological concepts of vaccine adjuvant activity |
| Q38113210 | Immunology and bone |
| Q33805719 | Immunomodulation by blockade of the TRANCE co-stimulatory pathway in murine allogeneic islet transplantation |
| Q38096027 | Importance of reverse signaling of the TNF superfamily in immune regulation. |
| Q42753302 | Inducible costimulator protein (ICOS) controls T helper cell subset polarization after virus and parasite infection |
| Q35643989 | Infections in postmenopausal women with osteoporosis treated with denosumab or placebo: coincidence or causal association? |
| Q41298079 | Inhibition of SIRPα in dendritic cells potentiates potent antitumor immunity |
| Q28727655 | Long-term treatment of osteoporosis: safety and efficacy appraisal of denosumab |
| Q45067678 | Loss of CD154 impairs the Th2 extrafollicular plasma cell response but not early T cell proliferation and interleukin-4 induction. |
| Q34006404 | Marrow-derived CD40-positive cells are required for mice to clear Cryptosporidium parvum infection |
| Q33850510 | Mature dendritic cells infected with canarypox virus elicit strong anti-human immunodeficiency virus CD8+ and CD4+ T-cell responses from chronically infected individuals |
| Q52578848 | Mechanisms involved in normal and pathological osteoclastogenesis. |
| Q34106530 | Molecular control of bone remodeling and osteoporosis |
| Q35664993 | Molecular mechanisms of the biphasic effects of interferon-γ on osteoclastogenesis |
| Q40671984 | Naturally occurring human IgM antibody that binds B7-DC and potentiates T cell stimulation by dendritic cells |
| Q36375728 | Neonatal tumor necrosis factor alpha promotes diabetes in nonobese diabetic mice by CD154-independent antigen presentation to CD8(+) T cells. |
| Q36866291 | New and emerging therapies for bone metastases in genitourinary cancers |
| Q40907799 | OX40-deficient mice are defective in Th cell proliferation but are competent in generating B cell and CTL Responses after virus infection |
| Q36938511 | Oral mucosal dendritic cells and periodontitis: many sides of the same coin with new twists |
| Q37489600 | Osteoclasts and the immune system |
| Q35755039 | Osteoclasts: New Insights |
| Q37949580 | Osteoimmunology - Unleashing the concepts |
| Q37626412 | Osteoimmunology and the effects of the immune system on bone |
| Q37544448 | Osteoimmunology: crosstalk between the immune and bone systems |
| Q24655113 | Osteoimmunology: interactions of the bone and immune system |
| Q28294477 | Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems |
| Q34079327 | Osteoprotegerin ligand: a regulator of immune responses and bone physiology. |
| Q77704341 | Pancreatic lymph node-derived CD4(+)CD25(+) Treg cells: highly potent regulators of diabetes that require TRANCE-RANK signals |
| Q33862741 | Pretreatment levels of soluble cellular receptors and interleukin-6 are associated with HIV disease progression in subjects treated with highly active antiretroviral therapy |
| Q24598872 | RANK is essential for osteoclast and lymph node development |
| Q37738754 | RANK ligand: effects of inhibition. |
| Q35053943 | RANK-Fc: a therapeutic antagonist for RANK-L in myeloma |
| Q27674275 | RANKL Employs Distinct Binding Modes to Engage RANK and the Osteoprotegerin Decoy Receptor |
| Q29397534 | RANKL Is Necessary and Sufficient to Initiate Development of Antigen-Sampling M Cells in the Intestinal Epithelium |
| Q53487298 | RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation. |
| Q37532561 | RANKL inhibition for the management of patients with benign metabolic bone disorders. |
| Q36412789 | RANKL-RANK interaction in immune regulatory systems |
| Q35875298 | Recent areas of development for dendritic cell vaccines. |
| Q36860987 | Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. |
| Q34086847 | Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases |
| Q37118177 | Reengineering dendritic cell-based anti-cancer vaccines |
| Q42202681 | Regulation of osteoclastogenesis by integrated signals from toll-like receptors |
| Q81610570 | Role of CD40-CD154 pathway in the rejection of concordant and discordant xenogeneic islets |
| Q90884836 | Role of RANK-L as a potential inducer of ILC2-mediated type 2 inflammation in chronic rhinosinusitis with nasal polyps |
| Q34963016 | Role of RANKL and RANK in bone loss and arthritis. |
| Q60489259 | Roles of the RANKL–RANK axis in antitumour immunity — implications for therapy |
| Q34090842 | Selective targeting of RANK signaling pathways as new therapeutic strategies for osteoporosis. |
| Q77148436 | T helper cells, IL-2 and the generation of cytotoxic T-cell responses |
| Q35179608 | T-cell involvement in osteoclast biology: implications for rheumatoid bone erosion |
| Q28142620 | TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src |
| Q36375923 | TRANCE, a tumor necrosis factor family member, enhances the longevity and adjuvant properties of dendritic cells in vivo |
| Q53912448 | TRANCE-RANK Costimulation is Required for IL-12 Production and the Initiation of a Th1-Type Response toLeishmania majorInfection in CD40L-Deficient Mice |
| Q42944002 | TRANCE-RANK, a new signal pathway involved in lymphocyte development and T cell activation |
| Q56905959 | The CD28-related molecule ICOS is required for effective T cell-dependent immune responses |
| Q33814962 | The initiation of autoimmune diabetes |
| Q33729251 | Thymic homing of activated CD4+ T cells induces degeneration of the thymic epithelium through excessive RANK signaling |
| Q34786965 | Transient blockade of CD40 ligand dissociates pathogenic from protective mucosal immunity |
| Q38530619 | Tumor necrosis factor receptor- associated factor 6 (TRAF6) regulation of development, function, and homeostasis of the immune system |
| Q33713257 | Tumor necrosis factor-alpha and the progression of diabetes in non-obese diabetic mice |
| Q36380499 | Tumor necrosis factor/tumor necrosis factor receptor family members that positively regulate immunity |
| Q36604777 | Why can't the immune system control HIV-1? Defining HIV-1-specific CD4+ T cell immunity in order to develop strategies to enhance viral immunity |
Search more.